| EX1512 MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR MULTIPLE MYELOMA |
| Specimen: |
3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube. Mix thoroughly & Ship immediately at 18-22°C or at 2-8°C. DO NOT FREEZE. |
| Stability: |
| Room |
Refrigerated |
Frozen |
| 72 hrs |
72 hrs |
NA |
|
| Method: |
FLOW CYTOMETRY |
| Comment: |
It is recommended that specimens arrive within 48 hours of drawing. The percentage of clonal plasma cells estimated by flow cytometry is affected by specimen processing and antigen loss with specimen aging. Pre-test information to accompany the specimen. |
| Report: |
Contact us to know the TAT. |
| Usage: |
Detection of minimal residual disease in Multiple Myeloma predicts outcome, helps identify an impending relapse and enables early intervention, better post-transplant surveillance, and better clinical management of patients. It can detect sub-microscopic levels of leukemia. MRD negativity is associated with improved PFS and OS. The prognostic impact of MRD negativity is independent of induction therapy. |
| Doctor Specialty: |
Oncologist |
| Disease: |
Multiple Myeloma |
| Components: |
*CD45 *CD19 *CD20 *CD27 *CD38 *CD138 *CD56 *CD117 *CD200 *CD81 *Kappa *Lambda |
| Courier Charges: |
|
| Home Collection: |
Available (*T&C Apply) |
| Department: |
FLOW CYTOMETRY |
| Pre Test Information: |
The following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History specially mention if the patient is on anti-CD38 therapy; original TRF; Date and time when the sample was drawn; 1 or 2 unstained BMA smears to be made at source. |
Reviews
There are no reviews yet.